Kindred Companion Sciences, a biotechnology firm, announced it bred two beagles, Bailey and Alfie, in September 2024 using CRISPR-based gene editing to eliminate Can f 1, the primary dog allergen. This unprecedented manipulation of canine genetics occurred despite the U.S. Food and Drug Administration's continued lack of approval for the company's gene-editing tools. The company's claim, published in a USA TODAY article on August 7, 2026, marks the first time genome editing has been deployed to modify dog allergens at their source.
The company asserts that both dogs are experiencing normal growth and development in their second year of life. This assurance comes without the full regulatory endorsement typically expected for such profound biological interventions. The genetic editing was reportedly conducted under U.S. federal standards for animal care and use, a standard that does not address the broader implications of altering species at a fundamental level.
Unapproved Alterations
National Institutes of Health data indicates that dog and cat allergies impact between 10% and 20% of the global population. Existing methods for managing these allergies focus on controlling the human immune response, not on altering the animals themselves. A March 2024 NIH study, now in its second year, confirmed that no dog, cat, or horse breed is truly hypoallergenic, stating that "Breeds marketed as hypoallergenic do not yield consistently lower environmental exposure" and "These approaches do not alter the underlying expression of Can f 1."
Can f 1 is produced from sebaceous glands, which are oil-producing glands on the skin, and from the tongue's outer layer of cells, known as tongue epithelial tissue. The new corporate approach bypasses traditional breeding and natural selection, directly editing the genetic code to remove a natural biological function. This represents a significant shift from managing a human condition to fundamentally altering another species for human convenience.
Redefining Life Itself
This work by Kindred Companion Sciences is not an isolated incident; it arrives amid a broader, accelerating interest in editing animal genes by private corporations. Colossal Biosciences, a Texas-based genetic engineering company, announced last year that it had resurrected the dire wolf from extinction. This firm bred three dire wolf puppies using extracted DNA from a 13,000-year-old tooth and a 72,000-year-old skull.
Researchers at Colossal Biosciences created two dire wolf genomes from these ancient specimens, comparing them with other canid species. They then edited 14 genes found in modern gray wolves to replicate specific extinct traits of the dire wolf, which previously existed 13,000 years ago, stood about 3½ feet tall, and could weigh up to 150 pounds. Domestic dogs were subsequently used as surrogate mothers for these genetically engineered wolves, blurring the lines between species and natural processes.
Elite Preferences, Corporate Solutions
Hypoallergenic dogs have seen a surge in popularity, particularly among the political class. Bo and Sunny, a pair of Portuguese Water Dogs, joined the Obama family in 2009 and 2013, 17 years and 13 years ago respectively, due to Malia Obama's canine allergies. This trend highlights how elite preferences can drive market demand for genetically modified solutions, pushing corporate science to bypass natural limitations and regulatory caution. The pursuit of such alterations by private entities, without full public or governmental oversight, signals a growing corporate power to redefine the natural world.